Clinical trial: Oral drug keeps cancer treatment on track for patients who develop persistently low platelet counts

In a signifier 2 objective trial, Mass General Brigham Cancer Institute researchers recovered that the oral cause avatrombopag was harmless and effectual successful managing persistent chemotherapy-induced thrombocytopenia (CIT) successful much than fractional of patients with gastrointestinal cancers, offering a imaginable caller enactment for managing a communal and challenging complication of crab treatment. Their enactment is published successful the Journal of Clinical Oncology.